Association Between Relative Fat Mass and the Serum Creatinine/Cystatin C Ratio and Cardiometabolic Multimorbidity: Evidence From Two Large Population‐Based Surveys
Journal of Diabetes Research · 2025
DOI: 10.1155/jdr/4075738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2025. Verfasst von Yanfen Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Endocrinology, Metabolism and Respiratory (the Cadre Ward), The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'a…. Hauptthemen laut MEDLINE: Creatinine, Cystatin C, Cardiovascular Diseases, Adipose Tissue. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The serum creatinine–cystatin C ratio (SCR/CysC) and relative fat mass (RFM) are both important indicators reflecting muscle and fat content, respectively, and are closely related to metabolic diseases and cardiovascular diseases. However, the roles of SCR/CysC and RFM in cardiometabolic multimorbidity (CMM) remain unclear. This study is aimed at exploring the relationships between SCR/CysC, RFM, and CMM, providing a new perspective for the early identification and intervention of CMM.
Methods
This study included 9292 Chinese participants from the CHARLS database and 3822 American individuals from the NHANES database. Multivariate logistic regression analysis, restricted cubic spline (RCS) plots, and subgroup analyses were employed to explore the associations of SCR/CysC and RFM with CMM.
Results
Analyses based on two databases revealed that the level of SCR/CysC levels was significantly negatively correlated with the risk of CMM. Conversely, higher RFM levels were positively correlated with an increased risk of CMM. Specifically, compared to the lower quartile (Q1) of SCR/CysC, the highest quartile (Q4) was associated with a decreased risk of CMM (CHARLS: odds ratio (OR) = 0.89, 95% confidence interval (CI): 0.87–0.91, p < 0.001; NHANES: OR = 0.90, 95% CI: 0.86–0.94, p < 0.001). Compared to the lower quartile (Q1) of RFM, the highest quartile (Q4) was associated with an increased risk of CMM (CHARLS: OR = 1.18, 95% CI: 1.16–1.21, p < 0.001; NHANES: OR = 1.20, 95% CI: 1.15–1.25, p < 0.001). The RCS plot results further supported this relationship, demonstrating that after adjusting for multiple confounding factors, a decrease in SCR/CysC and an increase in RFM were both associated with a higher risk of CMM.
Conclusions
This study found that SCR/CysC levels were negatively correlated with CMM risk, whereas RFM levels showed a positive correlation. Thus, SCR/CysC and RFM may both serve as potential biomarkers for CMM screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Endocrinology, Metabolism and Respiratory (the Cadre Ward), The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China, xjtu.edu.cn.
- Institute of Jianjiyue Biomedical Research Center, Xi'an, Shaanxi, China.
ORCID-Profile: Yanfen Hu, Lingxia Li
Zitieren
APA
Hu, Y., Li, L., Yan, L., Zhao, X., Wang, Q., & Xu, Z. (2025). Association Between Relative Fat Mass and the Serum Creatinine/Cystatin C Ratio and Cardiometabolic Multimorbidity: Evidence From Two Large Population‐Based Surveys. Journal of Diabetes Research. https://doi.org/10.1155/jdr/4075738
Vancouver
Hu Y, Li L, Yan L, Zhao X, Wang Q, Xu Z. Association Between Relative Fat Mass and the Serum Creatinine/Cystatin C Ratio and Cardiometabolic Multimorbidity: Evidence From Two Large Population‐Based Surveys. Journal of Diabetes Research. 2025. doi:10.1155/jdr/4075738
BibTeX
@article{Hu2025,
author = {Hu, Yanfen and Li, Lingxia and Yan, Ling and Zhao, Xiaoting and Wang, Qinfan and Xu, Zhenjie},
title = {Association Between Relative Fat Mass and the Serum Creatinine/Cystatin C Ratio and Cardiometabolic Multimorbidity: Evidence From Two Large Population‐Based Surveys},
journal = {Journal of Diabetes Research},
year = {2025},
doi = {10.1155/jdr/4075738}
}
EUVIMED